Zhaotai Cell Biology Technology

Hunan Zhaotai Cell Biology Technology is a clinical-stage biotechnology company based in Changsha, China, specializing in the development of advanced immune cell therapies. The company utilizes its proprietary Z-CAR platform to engineer next-generation Chimeric Antigen Receptor (CAR) T-cell and CAR-NK therapies designed to treat both hematological malignancies and solid tumors. Its pipeline features candidates targeting CD19, BCMA, and GPC3, with several programs currently undergoing clinical trials in China and the United States. Zhaotai is also expanding its research into the application of cell therapies for autoimmune diseases and high-incidence solid cancers like hepatocellular carcinoma. The firm emphasizes vertically integrated capabilities, including its own R&D centers and GMP-compliant manufacturing facilities.